Category - Developments

Developments

Altamira completes patient enrollment in house dust mite allergy trial with Bentrio

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment with its Bentrio nasal spray in a house dust mite allergic rhinitis trial and expects to release top-line results from the trial during the second quarter...

March 15, 2022

Developments

Profound Medical CEO adds to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired a total of 60,599 shares of Profound on the open market at a cost of $497,180 (U.S.). According to a filing with SEDI, Dr. Menawat...

March 11, 2022

Developments

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

March 11, 2022

Developments

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira Therapeutics’ (NASDAQ:CYTO) affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of its Bentrio nasal spray in COVID-19 patients. The COVAMID study is a...

March 9, 2022

Developments

Cannabotech technology eliminated 90%-plus of colon cancer cells in cell model

Closely-held Cannabotech of Israel reports that its cell model study results have shown that its integrative colon products killed more than 90% of colon cancer cells in a cell model experiment. The integrative colon...

March 7, 2022

Developments

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Altamira Therapeutics (NASDAQ:CYTO) entered into an exclusive licensing and distribution agreement with Nuance Pharma for Altamira’s Bentrio nasal spray for protection against airborne viruses and allergens in the...

March 4, 2022

Developments

Aravive posts positive updated Phase 1b data in clear cell renal cell carcinoma

Aravive (NASDAQ:ARAV) reported positive new data from the Phase 1b portion of an ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and new data from a biomarker high subgroup. Key findings...

March 3, 2022

Developments

FDA accepts LENSAR 510(k) submission for ALLY

The FDA accepted a 510(k) submission from LENSAR (NASDAQ:LNSR) for its next-generation ALLY Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY and is the...

March 1, 2022

Developments

Profound Medical’s TULSA-PRO now compatible with GE Healthcare’s 3T MRI scanners

Profound Medical (NASDAQ:PROF; TSX:PRN) announced the TULSA-PRO system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (MRI) scanners. Profound subsequently signed the first site agreement for a...

March 1, 2022

Developments

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Sigyn Therapeutics (OTC:SIGY) reported successful completion of an in vivo study that demonstrated Sigyn Therapy, its novel blood purification technology, to be safe and well tolerated. Data resulting from...

February 23, 2022

Category - Developments

Altamira completes patient enrollment in house dust mite allergy trial with Bentrio

Profound Medical CEO adds to holdings

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Cannabotech technology eliminated 90%-plus of colon cancer cells in cell model

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Aravive posts positive updated Phase 1b data in clear cell renal cell carcinoma

FDA accepts LENSAR 510(k) submission for ALLY

Profound Medical’s TULSA-PRO now compatible with GE Healthcare’s 3T MRI scanners

Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

General

More